Synthesis and antiulcer activity evaluation of conjugates of amino acids with N-aroyl- N, N'-dicyclohexyl urea.

Amino acids are safe molecules with variable efficacy against ulceration. Considering the good antioxidant potential of N-aroyl- N, N'-dicyclohexyl urea and antiulcer activities of amino acids, a series of amino acid conjugates of N-aroyl- N, N'-dicyclohexyl urea was synthesized and the effect against ulceration in albino rats induced by pyloric ligation was screened. All these compounds were found to be safe and active. Reduction of ulcer index was significant for all compounds. Conjugates of methionine and histidine exhibited enhanced antiulcer activity comparable to omeprazole in terms of inhibition of release of gastric juice, hydrochloric acid and neutralization activity. The promising efficacy and safety of these compounds is interesting for further investigation.

Background

Intraduodenal administration of mixed amino acid solution has been reported to significantly inhibit gastric acid secretion and gastrin release, stimulated by intragastric perfusion of peptone [1]. However studies conducted with individual amino acids have yielded varying results. Amino acids such as leucine, isoleucine and proline augment the acid release [2,3], where as amino acids including L-serine [4], L-tryptophan, L-arginine, glycine [5,6], tyrosine- and L-glutamic acid [7] have been shown to provide protection against gastric ulcers. Conjugate of methionine with penta-O-acetylglycyrrhizic acid healed both acute and chronic ulcers of rat stomach mucous lining and had low toxicity [8]. Esters of glycine, valine, leucine, proline and tryptophan with labdane diterpene imbricatolic acid exhibited strong gastro-protective action [9]. Although the mechanism of antiulcer action of individual amino acids is not clear, their N-acylated derivatives have been shown to have direct in vitro H+/K+ ATPase inhibitory activity as well as in vivo efficacy in pylorus ligation model [10]. Further radicals are the major causative factor in stress induced gastric ulceration [11] and antioxidants provide effective gastro protection against stress induced ulceration [12].

With this background and keeping in view the good antioxidant activity of N-aroyl- N, N'-dicyclohexyl urea analogs [13], studies were undertaken to synthesize their amino acid conjugates and evaluate their in vivo antiulcer efficacy against pylorus ligation model.

Results and Discussion

Chemistry

The N-cyclohexyl-N-(cyclohexylcarbamoyl) benzamide (1) was prepared by reacting N, N'-dicyclohexylcarbodiimide (DCC) with benzoic acid in the reported manner [13]. Equimolar quantity of benzoic acid and DCC were used with triethylamine (TEA) as catalyst. Reaction of dry toluene in presence of TEA generated the carboxylate anion that acted as nucleophile to undergo nucleophillic addition with DCC to give the O-aryl intermediate that upon rearrangement yielded the urea analogue N-cyclohexyl-N-(cyclohexylcarbamoyl) benzamide (scheme 1). Acylation of N-cyclohexyl-N-(cyclohexylcarbamoyl) benzamide with chloroacetyl chloride was carried out following reported method [14,15]. The TEA acted as catalyst to enhance the nucleophilicity of the secondary amine to attack the nucleophillic centre of the chloroacetyl chloride to give N-((2-chloroacetyl) (cyclohexyl) carbamoyl)-N-cyclohexyl benzamide (scheme 1). The reaction between amino acids and halohydrocarbon has been reported being carried out in presence of K2CO3 using methanol as solvent [15]. To develop a simple method for substitution reaction of N-((2-chloroacetyl) (cyclohexyl) carbamoyl)-N-cyclohexyl benzamide with amino acids, we screened the effect of the base and solvent on the yield of the reaction (Table 1). In this reaction proton is abstracted from the amino group of the amino acids producing the anion that reacts with the nucleophillic centre of the halohydrocarbon. From the table it can be seen that methanol-TEA system effectively promoted this reaction. Other base-solvent systems were less effective in facilitating the reaction. This can be attributed to the good polarity of methanol and appropriate basicity of TEA.

Scheme 1

Synthesis of amino acid conjugates of N-aroyl- N, N'-dicyclohexyl urea.

Table 1

The substitution reaction between tyrosine and N-((2-chloroacetyl) (cyclohexyl) carbamoyl) N-cyclohexyl benzamide

No	Solvent	Base	Time (h)	Yield (%)
1	MeOH	K2CO3	9	63
2	MeOH	TEA	8	76
3	MeOH	KOH	8	50
4	THF	K2CO3	8	43
5	THF	TEA	9	48
6	THF	KOH	10	35
7	Acetonitrile	K2CO3	8	35
8	Acetonitrile	TEA	8	28
9	Acetonitrile	KOH	10	22

Bioactivity

Oral acute toxicity study of the synthesized compounds was made by guidelines of Organization of Economic Co-operation and Development (OECD-423) for testing of chemicals. The dose was increased up to 3000 mg/kg (ip) and lethality was not observed till 3000 mg/kg indicating the safety of these compounds (3a-j). The antiulcer effects of the compounds were evaluated on white albino rats [16,17] according to internationally recognized guidelines with approved protocols from institutional animal ethics committee of School of Pharmaceutical Sciences with registration number 1171/c/08/cpcsea. One day before the induction of ulcers, the animals were divided into groups (n = 6) and drugs/vehicle was administered to white albino rats. The animals were then fasted (with free access to water) for a period of 24 h, so as to ensure complete gastric emptying and a steady state gastric acid secretion. The 24 h fasted animals were again administered with the drugs/vehicle on the morning of the experiment. Sixty minutes after administration of the drug/vehicle, the animals were anaesthetized using anesthetic ether and a midline incision was made just below the xiphoid process. The stomach was lifted out and ligated at the level of the pylorus following which it was replaced and the abdomen wall was closed by interrupted sutures. The animals were kept deprived of food and water and were sacrificed by an overdose of anesthetic ether after 4 h. The stomach was then dissected out, gastric contents were collected and subjected to centrifugation (1000 rpm for 10 min) and analysed for volume and pH. Free acidity and total acidity were estimated by titrating 1 mL of the centrifuged sample diluted to 10 mL with 0.01 N NaOH using Topfer's reagent and phenolphthalein indicator respectively. For estimation of ulcer index inner surface of the stomach was examined for ulceration with magnifying glass. Omeprazole (1 mg/kg) was used as the standard drug for comparison purpose. The difference between the groups was determined using the one-way analysis of variance (ANOVA).

The newly synthesized compounds exhibited variable antiulcer and antisecretory activity (Table 2). Reduction in volume of gastric juice was significant (P < 0.001) compared to control for 3a, 3b, 3c, 3d, 3g, 3h, 3i and 3j indicating their good antisecretory potential. The extent of reduction of secretion of gastric juice for compound 3b, 3c and 3j (Figure 1) was similar to that of omeprazole. The acid neutralizing capacity as indicated by pH of the gastric fluid was found to be more for compound 3j. All other compounds except 3e, 3f and 3h exhibited significant (P < 0.001) acid neutralizing capacity. Compound 3b and 3c showed antisecretory activity comparable to omeprazole but their acid neutralizing activity was found to be lower than the standard. Significant (P < 0.001) reduction in free acidity in all compounds except compound 3a indicated the ability of test compounds to inhibit secretion of hydrochloric acid. This inhibition was higher for the compound 3j and 3c followed by that of 3b. Reduction in free acidity of compound 3j and 3c was comparable to that of standard. All the compounds that inhibited free acidity, a proportionate inhibitory activity on total acidity was also observed (Figure 2). From the reduction in total acidity value, capacity of these compounds to reduce secretion as well as neutralize acid can be suggested. The inhibition of total acidity was highest for compounds 3c and 3j. The potential of the test compounds for inhibiting hydrochloric acid, gastric juice and neutralizing acidity has resulted in protection of gastric mucosa as observed from the significant (P < 0.001) decrease in ulcer index. From the analysis of the data it was observed that compound 3c containing methionine as the substituent and 3j with histidine as the substituent exhibited enhanced antiulcer activity that is comparable to omeprazole in terms of inhibition of release of gastric juice, hydrochloric acid and neutralization activity. Conjugates of tyrosine, serine, glutamine and cysteine exhibited similar anti-secretory and acid neutralizing capacity. Their antiulcer activity was significant compared to control but were less effective compared to conjugates of methionine and histidine. Conjugates of valine and threonine were least effective in reducing gastric volume. However the reduction of ulcer index was significant. This can be attributed to their effect on reduction of hydrochloric acid as observed from their free acidity and total acidity values. This study has yielded some very safe new compounds with good antiulcer potential.

Table 2

Antiulcer activity of compounds (3a-j)

Group	R	Volume(ml)	pH	Ulcer index	FA (meq./l)	TA (meq./l)
Control	-	6.40 ± 0.31	1.90 ± 0.26	16.80 ± 1.15	44.50 ± 3.09	48.72 ± 3.12
Standard	-	2.16 ± 0.28a	6.10 ± 0.28a	2.75 ± 0.42a	11.48 ± 1.52a	12.78 ± 1.73a
3a		4.33 ± 0.35a	3.50 ± 0.28a	5.91 ± 0.51a	33.17 ± 2.86b	37.83 ± 2.28b
3b		2.83 ± 0.31a	3.98 ± 0.25a	4.45 ± 0.32a	22.83 ± 3.17a	29.17 ± 2.66a
3c		2.38 ± 0.25a	4.23 ± 0.26a	3.81 ± 0.20a	14.05 ± 0.97a	16.82 ± 1.20a
3d		4.00 ± 0.36a	4.53 ± 0.34a	5.01 ± 0.47a	27.67 ± 2.87a	34.00 ± 3.36a
3e		5.03 ± 0.33	2.61 ± 0.30	6.93 ± 0.32a	26.33 ± 2.29a	31.67 ± 2.80a
3f		4.86 ± 0.35b	3.06 ± 0.39	5.85 ± 0.54a	24.67 ± 1.99a	29.50 ± 2.83a
3g		3.13 ± 0.44a	3.51 ± 0.28a	6.48 ± 0.41a	32.17 ± 2.52a	38.17 ± 2.63b
3h		4.38 ± 0.32a	3.13 ± 0.34b	5.31 ± 0.49a	28.83 ± 1.81a	33.33 ± 1.99a
3i		4.03 ± 0.53a	3.38 ± 0.28a	6.20 ± 0.40a	30.67 ± 3.49a	37.17 ± 3.60b
3j		2.36 ± 0.31a	5.28 ± 0.11a	3.31 ± 0.25	13.32 ± 1.70a	14.92 ± 1.86a
		F = 12.95	F = 15.58	F = 49.34	F = 14.72	F = 16.89

Data are represented as mean ± S.E.M Statistical analysis was done with one way analysis of variance (ANOVA). P < 0.001, P < 0.05 as compared to control (n = 6 in each group)

Figure 1

Effect of compounds (3a-j) on ulcer index, pH and gastric volume.

Figure 2

Reduction in free acidity and total acidity by the compounds (3a-j).

Experimental

All reagents and solvents were procured and used without further purification. Melting points were determined on a Sisco melting point apparatus and are uncorrected. Crude products were purified by column chromatography on silica gel of 60--120 mesh. Molecular weights of the compounds were determined by Rast's procedure. IR spectra were obtained on a JASCO FTIR-4100 spectrometer using KBr pellet. NMR spectra were recorded on BRUKER AVANCE-II- 400 MHz spectrometer using CDCl3. The chemical shifts were reported as ppm down field using tetramethylsilane (TMS) as an internal standard. Elemental analysis was carried out with PERKIN ELMER-2400 analyzer. Mass spectra were recorded on a MICROMASS Q-TOF MICRO spectrometer operating at 70 eV.

N-cyclohexyl-N-(cyclohexylcarbamoyl) benzamide (1)

N, N'-dicyclohexyl carbodiimide (1 mmol), benzoic acid (1 mmol) and triethylamine (1 mmol) in dry toluene (50 ml) was heated up to 110°C overnight to yield N-benzoyl-N, N'-dicyclohexylurea (1). The purity of the compound was checked with TLC. Yield 74%; Off-white; mp 112-115°C; FT-IR (KBr, cm-1): 3211.46 (N-H), 3022.74 (Ar-H), 2865.12 (C-H), 1685.12 (C = O);1H-NMR (CDCl3, 400 MHz):1.12-1.49 (20 H, m), 5.4 (1 H, s)7.6-8.1 (5 H, m).

N-((2-chloroacetyl) (cyclohexyl)carbamoyl)N-cyclohexyl benzamide (2)

To the well stirred solution of 1 (2 mmol) and triethylamine (2.2 mmol) in 50 ml benzene, chloro acetyl chloride (2.2 mmol) was added drop by drop for 30 min. It was stirred at room temperature for about 6 h. Progress of the reaction was monitored by TLC. After completion of reaction, the reaction mass was quenched in ice cold water and extracted in diethyl ether. The ether layer was washed twice with 5% NaHCO3 and twice with distilled water. Finally the ether layer was dried with anhydrous Na2SO4. Yield 70%; mp 121-123°C; White; FT-IR (KBr, cm-1): 3034.55 (Ar-H), 2845.58 (C-H), 1666.74 (C = O); 1H-NMR (CDCl3, 400 MHz): 1.11-1.47 (20 H, m), 3.41 (1 H, m), 4.17 (2 H, s), 7.1-8.25 (5 H, m).

(2S)-2-((2-3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl) amino)- 3- (4-hydroxyphenyl) propanoic acid (3a)

Tyrosine (1.2 mmol) in methanol (25 ml) was neutralized with triethylamine (1.2 mmol). To this K2CO3 (600 mg) was added. Later the solution of 2 (1 mmol) in methanol (50 ml) was added drop by drop for 30 min. The reaction mixture was refluxed for 8 h. The progress of the reaction was monitored by TLC. The reaction mixture was then desolventized and compound was extracted in ethyl acetate. The ethyl acetate layer was washed with water and dried over anhydrous Na2SO4. The product was further recrystallised from ethanol. Other compounds of the series 3b-j were obtained in a similar manner. Yield 75%; mp 124-126°C; Brown; Mol Wt. Anal. Found: 548.85. Calcd. for (C31H39N3O6): 549.28; FT-IR (KBr, cm-1): 3442.33 (O-H), 3029.12 (Ar-H), 2854.64 (C-H), 1669.87 (C = O); 1H-NMR(CDCl3, 400 MHz): 1.1-1.49 (m, 20H), 2.12 (s, 1H), 3.45-3.47(m, 1H), 3.89 (s, 1H), 5.86(s, 1H), 6.8-8.1(m, 9H). Anal. Found:C, 67.11; H, 8.03; N, 8.01 (%). Calcd. for (C31H39N3O6): C, 67.73; H, 7.15; N, 7.64 (%); MS (m/z): 549 (M+).

(2S)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-phenyl propanoic acid (3b)

Yield 64%; mp 133-135°C; White color; Mol Wt. Anal. Found: 532.72. Calcd. for (C31H39N3O5): 533.29; FT-IR(KBr, cm-1): 3445.69 (O-H), 2991.23 (Ar-H), 2837.85 (C-H), 1671.42 (C = O); 1H-NMR (CDCl3, 400 MHz): 1.2-1.45 (20 H, m), 2.15 (1 H, s), 3.49-3.51 (1 H, m), 3.74 (1 H, s), 7.1-8.1 (9 H m); Anal. Found: C, 69.17; H, 8.03; N, 7.25 (%). Calcd. for (C31H39N3O5): C, 69.76; H, 7.36; N, 7.87 (%);MS (m/z): 533 (M+).

(2S)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-hydroxy butanoic acid (3c)

Yield 72%; mp 136-138°C; Off white color; Mol Wt. Anal. Found: 487.85. Calcd. for (C26H37N3O6): 487.27; FT-IR (KBr, cm-1): 3317.45 (O-H), 2979.21 (Ar-H), 2854.33 (C-H), 1627.03 (C = O); 1H-NMR (CDCl3, 400 MHz): 1.05-1.48 (20 H, m), 2.08 (1 H, s), 3.94-3.99 (1 H, m), 4-4.016 (1 H, d), 7.26-7.76 (5 H, m); Anal. Found: C, 64.11; H, 8.03; N, 8.84 (%). Calcd. for (C26H37N3O6): C, 64.04; H, 7.64; N, 8.61 (%); MS(m/z): 487(M+).

(2R)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-hydroxy propanoic acid (3d)

Yield 55%; mp 117-119°C; Pale yellow; Mol Wt. Anal. Found: 473.1. Calcd. for (C25H35N3O6): 473.55; FT-IR (KBr, cm-1): 3511.21 (O-H), 3221.87 (N-H), 3011.55 (Ar-H), 2855.89 (C-H), 1642.32 (C = O); 1H-NMR(CDCl3, 400 MHz): 1.1-1.74 (20 H, m), 2 (1 H, s), 3.64 (s, 1H), 7.6-8.03 (5 H, m); Anal. Found: C, 63.01; H, 7.11; N, 8.23 (%). Calcd. for (C25H35N3O6): C, 63.40; H, 7.44; N, 8.87 (%).

(2R)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-methyl butanoic acid (3e)

Yield 49%; mp 130-132°C; Brown; Mol Wt. Anal. Found: 484.79. Calcd. for (C27H39N3O5): 485.29; FT-IR(KBr, cm-1): 3487.94 (O-H), 3189.76 (N-H), 3032.65 (Ar-H), 2834.95 (C-H), 1642.78 (C = O); 1H-NMR (CDCl3, 400 MHz): 0.82-0.93 (6 H, m), 1.12-1.44 (20 H, m), 2.34 (1 H, s), 7.31-7.98 (5 H, m); Anal. Found: C, 66.23; H, 7.89; N, 8.12 (%). Calcd. for (C27H39N3O5): C, 66.77; H, 8.09; N, 8.65 (%).

(2R)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-(methylthio) propanoic acid (3f)

Yield 56%; mp 141-143°C; White; Mol Wt. Anal. Found: 502.978. Calcd. for (C27H39N3O5S): 503.25;S, 5.98; FT-IR (KBr, cm-1): 3456.48 (O-H), 3211.13 (N-H), 3035.21 (Ar-H), 2865.45 (C-H), 1654.89 (C = O); 1H-NMR (CDCl3, 400 MHz): 1.11-1.7 (20 H, m), 2 (1 H, s), 3.89 (1 H, s), 7.6-8.2 (5 H, m); Anal. Found: C, 62.03; H, 7.11; N, 7.67 (%). Calcd.for (C27H39N3O5S): C, 62.64;H, 7.59; N, 8.11 (%); MS(m/z): 503(M+).

(2S)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-(1H-indol-3-yl) propanoic acid (3g)

Yield 53%; mp 127-129°C; Off-white; Mol Wt. Anal. Found: 571.65. Calcd. for (C33H40N4O5): 572.3; O;13.31;FT-IR (KBr, cm-1): 3445.53 (O-H), 3240.11(N-H), 3023.87 (Ar-H), 2854.43 (C-H), 1651.77 (C = O); 1H-NMR (CDCl3, 400 MHz): 1.2-1.74 (20 H, m), 2.1 (1 H, s), 3.54-3.7 (1 H, m), 7.18-8 (9 H, m), 9(1 H, s); Anal. Found: C, 68.68; H, 7.11; N, 9.41 (%). Calcd. for (C33H40N4O5): C, 69.20; H, 7.03; N, 9, 78 (%).

5-amino-(2S)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-5-oxo pentanoic acid (3h)

Yield 44%; mp 141-143°C; White; Mol Wt. Anal. Found: 513.74. Calcd. for (C27H38N4O6): 514.28; FT-IR (KBr, cm-1): 3432.67 (O-H), 3278.76 (N-H), 3176.54 (N-H), 3061.37 (Ar-H), 2845.33 (C-H), 1648.87 (C = O); 1H-NMR (CDCl3, 400 MHz): 1.11-1.74 (20 H, m), 1.8-1.95 (4 H, m), 2.1 (1 H, s), 3.49-3.7 (1 H, m), 6.5 (1 H, s), 7.7-8.3 (5 H, m); Anal. Found: C, 62.59; H, 7.11; N, 10.62 (%). Calcd. for (C27H38N4O6): C, 63.01; H, 7.44; N, 10.88 (%); MS(m/z): 514(M+).

(2R)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-mercapto propanoic acid (3i)

Yield 58%; mp 131-133°C; Brownish; Mol Wt. Anal. Found: 488.86. Calcd. for (C25H35N3O5S): 489. FT-IR (KBr, cm-1): 3423.12 (O-H), 3189.65 (N-H), 3033.79 (Ar-H), 2843.34 (C-H), 1666.54 (C = O); 1H-NMR(CDCl3, 400 MHz): 1.1-1.74 (20 H, m), 2.79-3.1 (2 H, m), 2 (1 H, s), 3.52-3.69 (1 H, m), 7.6-8.1 (5 H, m); Anal. Found: C, 54.98; H, 6.32; N, 9.10 (%). Calcd. for (C25H35N3O5S): C, 61.34; H, 7.15; N, 8.58 (%).

(2S)-2-((2-(3-benzoyl-1, 3-dicyclohexylureido)-2-oxoethyl)amino)-3-(1-H-imidazole-5-yl) propanoic acid (3j)

Yield 59%; Brown; Mol Wt. Anal. Found: 522.86. Calcd. for (C28H37N5O5): 523.28; FT-IR (KBr, cm-1): 3407.6(O-H), 2930.31(Ar-H), 2855 (C-H), 1627.83(C = O); 1H-NMR (CDCl3, 400 MHz): 1.12-1.88 (20 H, m), 2.12 (1 H, s), 2.54-2.56 (2 H, m), 3.39-3.44 (1 H, t), 3.77-3.81(1 H, m), 7.38-7.85 (5 H, m), 7.2-8.13 (5 H m,), 8.35 (1 H, s); Anal. Found: C, 64.42; H, 7.48; N, 13.24 (%). Calcd. for (C28H37N5O5): C, 64.22; H, 7.12; N, 13.37 (%); MS (m/z): 523.2(M+).

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BBS designed the study, carried out the synthesis, characterization, interpretation and drafted the manuscript.

SPS participated in the design of the study, synthesis, characterization and carried out pharmacological and statistical work